Tag Archives: 21st Century Cures

CLSA Applauds House Approval of H.R. 6, the 21st Century Cures Act

On July 10, the House of Representatives passed H.R. 6, the 21st Century Cures Act, by a vote of 344-77. Passage of this legislation is top priority of CLSA. The bill is aimed at accelerating the pace of biomedical innovation and cures by modernizing federal research and regulatory policies. This initiative was the result of more than a year of work by Energy & Commerce Committee Chairman Fred Upton (R-Mich.) and Rep. Diane DeGette (D-Colo.). CLSA contributed feedback throughout the process and were pleased to see several recommendations reflected in the passed legislation.

CLSA Applauds House Passage of 21st Century Cures Act

On July 10, the House overwhelmingly approved the 21st Cures Act, a comprehensive legislative package to accelerate the pace of biomedical research and development in the U.S. CLSA President & CEO Sara Radcliffe comments on the passage of this landmark legislation.

San Diego Union-Tribune: Opinion: Increased NIH funding helps find cures

Mark Stevenson, executive vice president of Thermo Fisher Scientific and president of its Life Sciences Solutions Group, pens an op-ed in The San Diego Union-Tribune encouraging Members of Congress to support efforts to increase NIH funding, which would improve patients’ lives and strengthen the economy.

Roll Call: Opinion: Applauding the 21st Century Cures Initiative

CLSA President & CEO Sara Radcliffe pens an exclusive op-ed in Roll Call applauding the 21st Century Cures Act. This landmark package of legislation includes a series of improvements to the healthcare system that will improve the lives of millions around the world, by accelerating the pace of drug, device and diagnostics discovery and development.

Roll Call: Opinion: The Wrong Direction on Patents

In the United States, protecting intellectual property is a bedrock principle. Without clear patent processes and strong enforcement rights, markets everywhere would be crippled by uncertainty. Investors could never be confident that companies actually own the innovations they are working to commercialize.

San Diego Union-Tribune: Opinion: Medical device tax repeal needed for health, economy

When the medical device tax was first proposed to help fund the Affordable Care Act (ACA), many people in government and the life sciences community expressed misgivings over its possible negative consequences. Unfortunately, those concerns have been substantiated by real-world experience. Since its implementation in 2013, this 2.3 percent excise tax has cost jobs, stifled innovation and will ultimately reduce access to lifesaving devices.